Back to Browse Journals » Clinical Ophthalmology » Volume 6

Multicenter, prospective, open-label, observational study of bimatoprost 0.01% in patients with primary open-angle glaucoma or ocular hypertension

Authors Pfennigsdorf S, Ramez O, von Kistowski G, Mäder B, Eschstruth P, Froböse M, Thelen U, Spraul C, Schnober D, Cooper H, Laube T

Published Date May 2012 Volume 2012:6 Pages 739—746


Received 1 March 2012, Accepted 26 March 2012, Published 11 May 2012

Stefan Pfennigsdorf,1 Osman Ramez,2 Gerrit von Kistowski,3 Birgit Mäder,4 Peter Eschstruth,5 Michael Froböse,6 Ulrich Thelen,7 Christoph Spraul,8 Dietmar Schnober,9 Hazel Cooper,10 Thomas Laube11

1Polch Ophthalmology Practice, Polch, 2Buxtehude Ophthalmology Practice, Buxtehude, 3Nürnberg Ophthalmology Practice, Nürnberg, 4Weißwasser Ophthalmology Practice, Weißwasser, 5Ophthalmology Practice, Kiel, 6Ophthalmology Practice, Bielefeld, 7Group Practice, Münster, 8Group Practice, Ulm, 9Ophthalmology Practice, Werdohl, Germany; 10Allergan, Marlow, UK, 11Group Practice, Düsseldorf, Germany

Background: Bimatoprost 0.01% was developed for improved tolerability over bimatoprost 0.03%, while maintaining efficacy in lowering intraocular pressure (IOP). This multicenter, prospective, open-label, observational study was designed to investigate the efficacy and tolerability of bimatoprost 0.01% in routine clinical practice.
Methods: Data were collected from 10,337 patients with primary open-angle glaucoma or ocular hypertension attending 1334 centers in Germany. The primary efficacy outcome was mean change in IOP in each eye from baseline to 10–14 weeks after initiation of bimatoprost 0.01%. Target IOP, prior therapies, additional treatments, and adverse events were also assessed. All treatment decisions were at the physicians’ discretion.
Results: Bimatoprost 0.01% significantly lowered mean IOP from baseline by –4.1 mmHg (P < 0.0001) in all patients after a mean of 10.45 weeks. In patients without previous treatment, bimatoprost 0.01% reduced mean IOP from baseline by –6.5 mmHg (P < 0.0001). Bimatoprost 0.01% also significantly reduced IOP in patients previously treated with monotherapy of β-blockers, prostaglandin analogs, carbonic anhydrase inhibitors or bimatoprost 0.03%. No adverse events were reported by 93.9% of patients during treatment with bimatoprost 0.01%; the most commonly reported adverse events were eye irritation (2.0%), ocular hyperemia (1.4%), and conjunctival hyperemia (1.2%). Physicians and patients rated tolerability and adherence as high, and most patients said they would continue with bimatoprost 0.01% treatment.
Conclusion: Bimatoprost 0.01% can produce additional IOP-lowering effects when used in routine clinical practice in patients who have received prior therapy, in addition to lowering IOP in previously untreated patients. A high rate of continuation of therapy with bimatoprost 0.01% was observed in patients who switched from a variety of different medications. The results suggest that bimatoprost 0.01% is a suitable first-choice therapy in patients with primary open-angle glaucoma or ocular hypertension.

Keywords: bimatoprost 0.01%, glaucoma, observational, ocular hypertension, intraocular pressure

Download Article [PDF] View Full Text [HTML] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at:

Other article by this author:

Readers of this article also read:

Intra-articular methotrexate associated to lipid nanoemulsions: anti-inflammatory effect upon antigen-induced arthritis

Mello SB, Tavares ER, Bulgarelli A, Bonfá E, Maranhão RC

International Journal of Nanomedicine 2013, 8:443-449

Published Date: 14 February 2013

An observational study of bimatoprost 0.01% in treatment-naïve patients with primary open angle glaucoma or ocular hypertension: the CLEAR trial

Nixon DR, Simonyi S, Bhogal M, Sigouin CS, Crichton AC, Discepola M, Hutnik CML, Yan DB

Clinical Ophthalmology 2012, 6:2097-2103

Published Date: 18 December 2012

Dexmedetomidine sedation in painful posterior segment surgery

Mansour A, Taha S

Clinical Ophthalmology 2012, 6:2075-2079

Published Date: 13 December 2012

Novel formulation of a methotrexate derivative with a lipid nanoemulsion

Moura JA, Valduga CJ, Tavares ER, Kretzer IF, Maria DA, Maranhao RC

International Journal of Nanomedicine 2011, 6:2285-2295

Published Date: 12 October 2011

Ocular hypotensive effect, preservation of visual fields, and safety of adding dorzolamide to prostaglandin therapy for twelve months

Kenji Inoue, Mieko Masumoto, Masato Wakakura, et al

Clinical Ophthalmology 2011, 5:393-396

Published Date: 22 March 2011

Identification of noncompliant glaucoma patients using Bayesian networks and the Eye-Drop Satisfaction Questionnaire

Jean-Philippe Nordmann, Christian Baudouin, Jean-Paul Renard, et al

Clinical Ophthalmology 2010, 4:1489-1495

Published Date: 8 December 2010

Fixed combination of bimatoprost and timolol in patients with primary open-angle glaucoma or ocular hypertension with inadequate IOP adjustment

Gerrett Brief, Tobias Lammich, Edgar Nagel, et al

Clinical Ophthalmology 2010, 4:1125-1129

Published Date: 29 September 2010

Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors

Eduardo Pimenta, Suzanne Oparil

Vascular Health and Risk Management 2009, 5:453-463

Published Date: 19 May 2009